



**Living Cell Technologies Limited**  
PO Box 3014, Auburn VIC 3123  
ABN: 14 104 028 042

## **Living Cell Technologies awarded NZ\$100,000 from NZ Government**

5 July, 2007, Melbourne, Australia and Auckland, New Zealand:

Living Cell Technologies Limited (ASX: LCT) today announced that it has been awarded an Enterprise Development Grant of NZ\$100,000 from New Zealand Trade & Enterprise to assist the Company's market development activities internationally.

Specifically the grant will assist with expenses relating to pitching LCT's pig cell therapeutics and pig tissue supply to in-market contacts, legal fees associated with market development and accessing local expertise for exploring co-development rights for LCT's products with potential strategic partners in the US, Europe and Russia.

"Continued significant support from the New Zealand Government and its agencies is particularly beneficial in LCT pursuing the range of opportunities available and within a reasonable timeframe," said LCT CEO, Dr Paul Tan.

"The grant enables LCT management to concentrate on key product development, while simultaneously exploring options for shareholder returns," Dr Tan said.

This investment follows on from two significant grants provided to LCT in 2006, totaling over \$3.2 million and supported by NZTE and the Foundation for Research, Science and Technology.

<b>Further information: <a href="http://www.lctglobal.com">www.lctglobal.com</a></b>	
Dr Paul Tan CEO Mobile: +61 402 716 984	Paris Brooke General Manager – LCT Mobile: + 61 407 715 574

### **About Living Cell Technologies: [www.lctglobal.com](http://www.lctglobal.com)**

*Living Cell is developing live cell therapy products to treat life threatening human diseases. The company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.*

---

---

#### **LCT disclaimer**

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will



satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of 5 July 2007 and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.